Ignite Creation Date:
2024-05-06 @ 2:00 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01942135
Status:
COMPLETED
Last Update Posted:
2024-04-04
First Post:
2013-09-10
Brief Title:
Palbociclib PD-0332991 Combined With Fulvestrant In Hormone Receptor HER2-Negative Metastatic Breast Cancer After Endocrine Failure PALOMA-3
Sponsor:
Organization:
Pfizer
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
521
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: